Clinical Trial Update: Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4) [Phase 3]

View source ↗

Summary

Phase 3 CHIME 4 trial evaluating impulsive aggression treatment in ADHD subjects terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• QELBREE (viloxazine hydrochloride)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | Status: TERMINATED | Results posted: 2024-05-16